![]() |
市場調查報告書
商品編碼
1827767
2025年全球眼部植入市場報告Ocular Implants Global Market Report 2025 |
近年來,眼部植入市場快速擴張,市場規模從2024年的147.6億美元成長至2025年的162.5億美元,複合年成長率為10.1%。預測期內的成長主要歸因於眼部外傷、視力矯正、糖尿病視網膜病變、眼科疾病以及監管核准。
預計未來幾年眼部植入市場將快速成長,到2029年將達到250.6億美元,複合年成長率為11.4%。預測期內的成長歸因於人口老化加劇、近視盛行率上升、青光眼管理、微創手術以及病人安全。預測期內的主要趨勢包括技術進步、眼科創新、數位醫療、再生醫學、數位醫療和人工智慧 (AI)。
眼部植入用於增強個人視力。這些植入有助於因受傷或疾病而失去眼睛的人恢復視力。這些植入物通常被稱為玻璃眼,由硬質塑膠丙烯酸製成。義眼呈貝殼狀,內含透明的人工水晶體植入,用於在白內障手術中替換混濁的自然水晶體。
眼部植入的主要產品類型包括人工水晶體、角膜植入、眼眶植入和青光眼植入。人工水晶體由透明塑膠、矽膠和丙烯酸等材料製成。這些水晶體屈光進入眼睛的光線,從而改善視力。此外,它們還塗有特殊材料,以保護眼睛免受太陽發出的有害紫外線的傷害。眼部植入被眼科機構、醫院和診所等終端使用者用於治療青光眼、糖尿病視網膜病變和老齡化性黃斑部病變。
2025年春季美國關稅的突然上調及其引發的貿易摩擦對醫療設備產業產生了重大影響,尤其對影像處理設備、手術用不銹鋼和一次性塑膠等進口零件產生了重大影響。由於醫院和診所抵制漲價,製造商面臨利潤壓力。監管挑戰進一步加劇了形勢,因為由於關稅而更換供應商通常需要醫療設備重新認證,導致市場准入延遲。為此,企業正在透過雙重採購關鍵零件、增加標準化產品的國內生產以及加快尋找更具成本效益的材料來降低風險。
本研究報告是商業研究公司 (The Business Research Company) 全新報告系列的一部分,該系列提供眼部植入市場統計數據,包括全球眼部植入市場規模、各地區市場佔有率、競爭對手的眼部植入市場佔有率、詳細的眼部植入細分市場、市場趨勢和商機,以及您在眼部植入行業取得成功所需的數據。本眼部植入市場研究報告對該行業的現狀和未來趨勢進行了詳細分析,為您提供所需的全方位觀點。
未來五年的預測成長率為11.4%,較我們先前對該市場的預測略有下降0.1%。這一下降主要源自於美國與其他國家之間關稅的影響。由於互惠關稅以及貿易緊張局勢和限制措施的加劇對全球經濟和貿易的負面影響,其影響將更加廣泛。
全球老年人口的成長預計將推動未來眼部植入市場的成長。老年人口通常指65歲及以上的人。眼部植入為常見的與老齡化相關的眼部疾病(如白內障、青光眼和老花眼)提供了解決方案,可以改善視力,減少對矯正眼鏡的需求,並提高老年人的生活品質。例如,2022年10月,總部位於瑞士的國際公共衛生組織世界衛生組織(WHO)預測,全球60歲以上人口將從2020年的10億增加到2022年的14億。此外,據估計,到2030年,全球六分之一的人將年滿60歲或以上。因此,全球老年人口的成長可能會刺激眼部植入市場的擴張。
全球範圍內眼科疾病的日益流行預計將極大地推動眼部植入市場的成長。在美國最常見的眼科疾病包括屈光不正。例如,2022 年,美國眼科學會 (AAO) 提供了按種族分類的與眼部疾病相關的視力障礙盛行率的統計數據,以及因這些疾病而法定失明的人數數據。光是在美國,就有大約 1,200 萬 40 歲及以上的人患有視力障礙,而全球整體約有 100 萬人失明。此外,根據世界衛生組織 (WHO) 的數據,全世界約有 22 億人患有眼睛或視力障礙。因此,預計白內障和青光眼等眼科疾病的盛行率將會上升,從而推動對眼部植入的需求。
眼部植入市場的主要企業專注於創造創新解決方案,例如Axitinib玻璃體內植入,以改善視網膜靜脈阻塞和糖尿病性黃斑部水腫等眼科疾病的治療選擇。Axitinib體內植入是一種小型藥物釋放裝置,直接插入眼部玻璃體腔,以受控、持續的方式輸送蛋白酪氨酸激酶抑制劑Axitinib。例如,美國製藥公司 Ocular Therapeutix, Inc. 已啟動其Axitinib體內植入物 (OTX-TKI) 治療濕性老齡化黃斑部病變(濕性 AMD) 的關鍵臨床試驗。該試驗旨在評估與阿柏西普標準治療相比,植入在保護視力方面的安全性和有效性。該試驗計劃為一項多中心、隨機試驗,涉及約 300 名患者,旨在探索 OTX-TKI藥物緩釋的潛力,從而減少有效治療所需的注射頻率。
眼科植入市場的主要企業正在推出創新的高品質虹膜植入產品,例如 ARTIFICIALIRIS SELECT,以獲得競爭優勢。 ARTIFICIALIRIS SELECT 是一種高級植入,可提供快速、可自訂的虹膜更換並增強患者護理。例如,德國醫療技術製造商 HumanOptics Holding AG 計劃於 2023 年 8 月推出其高級植入ARTIFICIALIRIS SELECT。該植入將提供多種顏色,包括棕色、藍色和綠色,每種顏色都有三種色調:淺色、中型和深色。此外,該植入將提供九種預先定義的顏色組合,確保快速有效地治療患者。外科醫生可以使用專門設計的 HumanOptics Color Chart SELECT 將色卡與患者的健康眼睛進行比較,輕鬆為患者選擇最合適的顏色。
2024年6月,美國製藥公司ANI Pharmaceuticals, Inc.收購了Alimera Sciences, Inc.,收購金額未揭露。此次收購將增強ANI Pharmaceuticals在罕見疾病和眼科領域的產品組合,使其能夠獲得兩項實用化的資產—Iluvien和Yutiq。預計這兩項資產將帶來顯著的收益成長,並提升ANI Pharmaceuticals在眼科領域的全球影響力。 Alimera Sciences, Inc.也是一家總部位於美國的製藥公司,專注於眼內植入。
眼部植入市場的主要企業包括 Alcon Inc.、Bausch & Lomb Inc.、Carl Zeiss AG、STAAR Surgical Company、Johnson and Johnson Services Inc.、Morcher GmbH、Aurolab Ltd.、Cornea Biosciences、KERAMED INC.、Price Vision Group、Gulden Ophan Ophatics Co.Owacyk、Jkak但是、Lomu 哇Inc.、SIFI SpA、Ophtec BV、HumanOptics AG、Medicontur Medical Engineering Ltd.、Hanita Lenses、Omni Lens Pvt. Ltd.、EyeKon Medical Inc.、FCI Ophthalmics Inc.、Santen Pharmaceutical Co. Ltd.、Ocular Therapeuvan Inc.、AcuFocus Inc.
2024年,北美是眼部植入市場最大的地區。預計亞太地區將成為預測期內成長最快的地區。眼部植入市場佔有率報告涵蓋亞太地區、西歐、中歐和東歐、北美、南美以及中東和非洲。
眼植入市場報告涉及的國家有澳洲、巴西、中國、法國、德國、印度、印尼、日本、俄羅斯、韓國、英國和美國。
眼部植入市場涵蓋單焦點、散光鏡片、多焦點和可調節晶體的銷售。該市場的價值指的是“出廠價”,即商品製造商或生產商銷售給其他營業單位(包括下游製造商、批發商、經銷商和零售商)或直接銷售給最終客戶的商品價值。該市場中的商品價值還包括商品製造商銷售的任何相關服務。
Ocular implants are employed to enhance the vision of individuals. These implants contribute to the restoration of sight in those who have lost an eye due to injury or disease, commonly known as a glass eye, typically crafted from hard plastic acrylic. The prosthetic eye takes the form of a shell, incorporating a clear, artificial lens implant utilized to substitute a clouded natural lens during cataract surgery.
The primary product categories within ocular implants encompass intraocular lenses, corneal implants, orbital implants, glaucoma implants, and others. Intraocular lenses are fashioned from materials such as clear plastic, silicone, or acrylic. These lenses refract light rays entering the eye, facilitating improved vision. Additionally, they are coated with a special material designed to shield the eyes from the harmful ultraviolet rays emitted by the sun. Ocular implants find application in procedures related to glaucoma, diabetic retinopathy, and age-related macular degeneration, and are utilized by end-users such as specialty eye institutes, hospitals, and clinics.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.
The ocular implants market research report is one of a series of new reports from The Business Research Company that provides ocular implants market statistics, including ocular implants industry global market size, regional shares, competitors with a ocular implants market share, detailed ocular implants market segments, market trends and opportunities, and any further data you may need to thrive in the ocular implants industry. This ocular implants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The ocular implants market size has grown rapidly in recent years. It will grow from $14.76 billion in 2024 to $16.25 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to ocular trauma, vision correction, diabetic retinopathy, eye diseases, regulatory approvals.
The ocular implants market size is expected to see rapid growth in the next few years. It will grow to $25.06 billion in 2029 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to growing aging population, rising myopia prevalence, glaucoma management, minimally invasive surgery, patient safety. Major trends in the forecast period include technological advancements, ophthalmic innovation, digital healthcare, regenerative medicine, digital healthcare, artificial intelligence (ai).
The forecast of 11.4% growth over the next five years indicates a slight reduction of 0.1% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through trade restrictions on German-sourced acrylic polymers, raising production costs for intraocular lenses and potentially delaying cataract surgery procedures for aging populations.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increase in the global geriatric population is anticipated to drive the growth of the ocular implants market in the future. The geriatric population refers to individuals typically aged 65 and older. Ocular implants offer solutions for common age-related eye conditions such as cataracts, glaucoma, and presbyopia, helping to improve vision, decrease the need for corrective eyewear, and enhance the quality of life for older adults. For example, in October 2022, the World Health Organization, an international public health organization based in Switzerland, projected that the global population of individuals aged 60 years and older would rise to 1.4 billion by 2022, up from 1 billion in 2020. Furthermore, by 2030, it is estimated that 1 in 6 people worldwide will be over 60 years of age. Thus, the growth of the geriatric population globally will stimulate the expansion of the ocular implants market.
The growing prevalence of eye disorders worldwide is expected to significantly drive the growth of the ocular implants market. The most common eye disorders in the U.S. include refractive errors. For example, in 2022, the American Academy of Ophthalmology (AAO) provided statistics on the prevalence of visual impairments related to eye disorders by ethnicity, as well as data on the number of individuals who are legally blind due to these conditions. In the United States alone, approximately 12 million people aged 40 and older experience vision impairment, with about one million suffering from blindness globally. Furthermore, reports indicate that around 2.2 billion individuals worldwide have eye and visual disorders, according to the World Health Organization. Consequently, the rising prevalence of eye disorders, including cataracts and glaucoma, is anticipated to increase the demand for ocular implants.
Major companies in the ocular implants market are concentrating on creating innovative solutions, such as axitinib intravitreal implants, to improve treatment options for eye diseases like retinal vein occlusion and diabetic macular edema. Axitinib intravitreal implants are small, drug-releasing devices inserted directly into the eye's vitreous cavity to deliver axitinib, a tyrosine kinase inhibitor, in a controlled and sustained manner. For example, Ocular Therapeutix, Inc., a U.S.-based pharmaceutical company, has initiated a pivotal clinical trial for its axitinib intravitreal implant, OTX-TKI, intended for the treatment of wet age-related macular degeneration (wet AMD). This trial aims to evaluate the safety and efficacy of the implant in preserving visual acuity compared to the standard treatment with aflibercept. Designed as a multi-center, randomized study involving approximately 300 patients, the trial seeks to determine the potential of OTX-TKI to provide a sustained release of the drug, which may reduce the frequency of injections needed for effective treatment.
Major companies in the ocular implant market are launching innovative and high-quality iris implant products, such as ARTIFICIALIRIS SELECT, to achieve a competitive edge. ARTIFICIALIRIS SELECT is a premium implant that provides expedited and customizable iris replacement to enhance patient care. For instance, in August 2023, HumanOptics Holding AG, a Germany-based medical technology manufacturer, is set to introduce the premium implant ARTIFICIALIRIS SELECT. This implant offers a variety of color options, including brown, blue, and green, each available in three different shades: light, medium, and dark. Additionally, the implant comes in nine predefined color combinations, ensuring prompt and efficient patient care. Surgeons can easily choose the most suitable color match for the patient by utilizing the specially designed HumanOptics Color Chart SELECT, allowing them to compare it with the patient's healthy eye.
In June 2024, ANI Pharmaceuticals, Inc., a US-based pharmaceutical company, acquired Alimera Sciences, Inc., for an undisclosed sum. This acquisition is intended to strengthen ANI Pharmaceuticals' rare disease segment and ophthalmology portfolio, providing access to two commercially viable assets, Iluvien and Yutiq, which are anticipated to drive substantial revenue growth and enhance ANI's global footprint in the ophthalmology market. Alimera Sciences, Inc., also a US-based pharmaceutical company, specializes in intravitreal (back of the eye) implants.
Major companies operating in the ocular implants market include Alcon Inc., Bausch & Lomb Inc., Carl Zeiss AG, STAAR Surgical Company, Johnson and Johnson Services Inc., Morcher GmbH, Aurolab Ltd., Cornea Biosciences, KERAMED INC., Price Vision Group, Gulden Ophthalmics Co. Inc., AJL Ophthalmic SA, Hoya Corp., Rayner Intraocular Lenses Limited, Lenstec Inc., SIFI S.p.A, Ophtec BV, HumanOptics AG, Medicontur Medical Engineering Ltd., Hanita Lenses, Omni Lens Pvt. Ltd., EyeKon Medical Inc., FCI Ophthalmics Inc., Santen Pharmaceutical Co. Ltd., Ocular Therapeutix Inc., AcuFocus Inc., Glaukos Corporation, Ivantis Inc.
North America was the largest region in the ocular implants market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ocular implants market share report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.
The countries covered in the ocular implants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.
The ocular implants market consists of sales of monofocal lens, toric lens, multifocal and accommodating lenses. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Ocular Implants Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on ocular implants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for ocular implants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ocular implants market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.